Drug profile · INN
ex vivo expanded autologous human corneal epithelial cells containing stem cells
HOLOCLAR
ex vivo expanded autologous human corneal epithelial cells containing stem cells (HOLOCLAR) is a somatic cell supplemental therapy.
EMA: approved Sensory organs (S01) S01XA19
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — ex vivo expanded autologous human corneal epithelial cells containing stem cells
- Class
- Sensory organs (S01)
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.83
Quick answer
ex vivo expanded autologous human corneal epithelial cells containing stem cells (HOLOCLAR) is a somatic cell supplemental therapy.
Key facts
INN ex vivo expanded autologous human corneal epithelial cells containing stem cells
Brand HOLOCLAR
Mechanism Somatic cell supplemental therapy
Therapeutic class Sensory organs (S01)
ATC code S01XA19
Mechanism of action
Somatic cell supplemental therapy
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ex vivo expanded autologous human corneal epithelial cells containing stem cells?
ex vivo expanded autologous human corneal epithelial cells containing stem cells (HOLOCLAR) is a somatic cell supplemental therapy.
What is the brand name for ex vivo expanded autologous human corneal epithelial cells containing stem cells?
HOLOCLAR is a marketed brand name for ex vivo expanded autologous human corneal epithelial cells containing stem cells. Check FDA Drugs@FDA for the current US label holder and prescribing information.